Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
April 27, 2023 03:20 ET
|
Arbutus Biopharma Corporation
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV...
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting
April 24, 2023 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated with continued seizure reduction of >90% in the first two patients at nine- and five-months post-treatment, respectively Impaired-awareness seizures...
Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
April 24, 2023 05:00 ET
|
Medigene AG
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early...
H1.co Named 2023 Website of the Year by the Health And IT Marketing Community
April 18, 2023 09:00 ET
|
H1
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, is proud to announce that it has been awarded the...
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
February 14, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
January 09, 2023 01:20 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Crypto Health Market Research Report - Global Forecast to 2027 - Cumulative Impact of COVID-19
December 20, 2022 04:03 ET
|
Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Crypto Health Market Research Report by Function, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ...
Mendus AB: Mendus presenterar positiva överlevnadsdata från ADVANCE II-studien, som utvärderar DCP-001 som underhållsbehandling vid AML, på American Society of Hematology (ASH)
December 12, 2022 13:00 ET
|
Mendus AB
TISDAGEN DEN 13 DECEMBER 2022, KLOCKAN 8.00AM ET/2.00PM CET, GENOMFÖR MENDUS ETT WEBBSÄNT MÖTE, DÄR RESULTATEN SOM PRESENTERATS PÅ ASH KOMMER ATT DISKUTERAS Mendus AB (“Mendus” publ; IMMU.ST),...
Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting
December 12, 2022 13:00 ET
|
Mendus AB
MENDUS TO HOST A WEBCAST TO DISCUSS THE ASH DATA ON TUESDAY, DECEMBER 13, 2022 AT 8.00AM ET/2.00PM CET Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Healthcare Data Leader H1 Releases Its Top Predictions for 2023
December 07, 2022 09:00 ET
|
H1
NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, today released its predictions for 2023 to help life...